October 25, 2018

MC2 Therapeutics appoints Christopher S. Billis as Chief Commercial Officer

Copenhagen, October 25th, 2018 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that it has appointed Christopher S. Billis, an experienced healthcare executive within the field of dermatology, as Chief Commercial Officer.

Mr. Billis brings more than 24 years of pharmaceutical commercialization and operational experience to MC2 Therapeutics. Mr. Billis has a substantial experience with global pharmaceutical companies and has successfully launched products, grown product franchises and transacted deals to build portfolios within the fields of dermatology and OTC products.

Chris’ insight in market dynamics, strategic perspective and operational experience will be extremely valuable to the MC2 Therapeutics team as the company builds a commercial infrastructure aiming to launch first products in 2019. Markets are undergoing fundamental changes and we aim to develop next generation commercialization strategies based on profitable market access.” said Jesper J. Lange, President/CEO of MC2 Therapeutics.

MC2 Therapeutics recently announced very encouraging Ph3 results on its lead programs MC2-01 PAD™ Cream for treatment of psoriasis and Ph2 results on MC2-03 PAD™ Eye Drops for treatment of dry eye. The company has a strong pipeline of new topical therapies fueled by its PAD™ Technology – a new class of vehicle for topicals.

We aim to help patients with chronic skin or eye diseases to minimize the daily burden of disease by developing products that provide fast relief of symptoms while being pleasant to use in daily routines. It is critical that as many patients as possible can get access to our PAD™ based products – we remain agile and focused on execution.” said Mr. Lange and added: “Chris fits right into this strategy.”

Mr. Billis commented: “The MC2 team combines high integrity with technical grace to design products that make the lives of patients better across the globe and I could not be more excited or proud to be part of the team”. Mr. Billis joins MC2 Therapeutics from Bayer Healthcare Inc. where he most recently served as Head of Marketing, Dermatology. Prior to Bayer Healthcare Inc., Mr. Billis held commercial roles at Stiefel Laboratories.

About MC2 Therapeutics A/S

MC2 Therapeutics A/S is a privately held clinical-stage dermatology and eye care company. Using its proprietary PAD™ Technology – a new class of vehicle – MC2 Therapeutics is developing a pipeline of new highly efficacious topical therapies designed for unique patient experiences.